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Radiation  therapy  (with associated  chemotherapy)  is  the  standard  treatment  for  nasopharyngeal  carci-onformal intensity-modulated radiation
herapy
arget volumes
ate effects
erostomia
noma. Conformal  intensity-modulated  radiation  therapy  is  a new  and  particularly  interesting  technique
for  these  tumors,  due  to their  complex  volumes  close  to  many  critical  organs.  Better  dosimetric  results
and  improved  protection  of  adjacent  healthy  tissue  have  been  shown  compared  with  conventional  2D  or
3D  radiation  therapy,  with  signiﬁcantly  reduced  side-effects,  notably  xerostomia.  Excellent  local  control
rates have  been  reported.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Nasopharyngeal carcinoma, especially when of the undifferenti-
ted type, differs from other head and neck cancers geographically
nd ethnically and by its association with Epstein-Barr virus and
peciﬁc treatment requirements. Treatment is hindered by the
natomic proximity of numerous critical organs, restricting indi-
ations for surgery to biopsy for initial histologic diagnosis and
o cases of relapse. Radiation therapy (RT) is the keystone of local
reatment [1].
In locally advanced cancer, the overall survival beneﬁt of asso-
iating radiation therapy and chemotherapy was  demonstrated in
aujat et al.’s meta-analysis, especially when the association was
oncomitant [2].
The efﬁcacy of adjuvant chemotherapy is under assessment, cer-
ain retrospective reports suggesting an impact on tumor control
3].
Progress in imaging (magnetic resonance imaging (MRI) and
ositron emission tomography coupled to computed tomography
PET-CT)) has improved initial extension assessment in nasopha-
yngeal carcinoma [4], enhancing the precision of RT planning.
More recently, conformal intensity-modulated radiation ther-
py (IMRT) has become standard clinical practice.
IMRT uses multiple small radiation beams of varying intensities
nd shapes thanks to a multileaf collimator.
This optimizes tumor area coverage while protecting healthy
eighboring organs.
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879-7296/© 2014 Elsevier Masson SAS. All rights reserved.The present study successively examines the various radiation
target volumes and healthy organs to be spared (organs at-risk:
OARs) and the fractionation and dose options. We  shall also review
the data demonstrating the speciﬁc beneﬁt of IMRT over 2D and 3D
strategies. Finally, we  shall report results for local control, and look
at foreseeable future developments.
2. Deﬁnition of target volumes
RT planning requires target volumes to be deﬁned on a CT-scan
for dosimetry. This is performed in dorsal decubitus, with a 5-point
thermoformed contention mask (immobilization of head, neck and
shoulders), without and, if possible, with intravenous iodized con-
trast injection, and thin (3 mm)  slice acquisition from vertex to
superior mediastinum. The target volumes to be deﬁned are as
follows [5].
2.1. GTV
Gross tumor volume (GTV) is the tumor mass visible on clinical
examination, endoscopy and imaging. It includes the nasopharyn-
geal tumor (tumoral GTV) and involved lymph nodes (nodal GTV).
GTV after neoadjuvant chemotherapy includes not only the resid-
ual volume but the whole initial tumor and involved lymph nodes.
Delineation is improved by fusion of the planning CT scan and the
initial MRI. However attractive the option may  seem, fusion with
PET-CT is not recommended in routine practice, for lack of vali-
dation in the literature.
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Fig. 1. Example of CTV deﬁnition including nasopharynx, posterior third of nasal
cavities and maxillary sinuses (anteriorly), parapharyngeal space (laterally) and
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Retrospective studies of nasopharyngeal carcinoma indicate alivus and retropharyngeal space (posteriorly).
.2. CTV
Clinical target volume (CTV) includes GTV plus any immediately
eighboring microscopic tumor or lymph-node extensions, taking
ccount of the natural extension pathways of nasopharyngeal car-
inoma. CTV thus includes:
above: the inferior part of the sphenoid sinus, and the middle
cranial fossa, including foramina (ovale and lacerum);
below, the oropharyngeal mucosa;
laterally, the parapharyngeal spaces;
anteriorly, the posterior part of the nasal cavities and the ptery-
gomaxillary fossa;
posteriorly, the retropharyngeal space and clivus [1,6,7]
(Figs. 1 and 2).Some authors also include the cavernous sinus (superiorly),
terygoid muscles and carotid space (laterally) and the posterior
hird of the maxillary sinuses (anteriorly) in the CTV [7–9].
Fig. 2. Example of delineation with tumorngology, Head and Neck diseases 132 (2015) 147–151
Nasopharyngeal carcinoma being highly lymphophilic, nodal
CTV systematically includes bilateral levels II to V (Robbins classiﬁ-
cation) and the bilateral retropharyngeal lymph-node areas [10,11].
2.3. PTV
Planning target volume (PTV) is delineated geometrically by
drawing a 3–5 mm margin around the tumoral or lymph-node CTV,
to allow for uncertainty related to patient positioning and system-
atic or variable internal movement.
2.4. Organs at risk (OARs)
Healthy organs are also delineated, to ensure protection: brain-
stem, brain (temporal lobe and posterior fossa), spinal cord, optic
chiasm, cochlea, optic nerves, lens, parotid glands, submandibular
glands, mandible, temporomandibular joints, pharyngeal constric-
tor muscles, larynx, esophagus, and thyroid and pituitary glands.
3. IMRT dose prescription
IMRT uses 5 to 7 radiation beams, with ﬂuence adjusted from
fraction to fraction. Planning is inverse: i.e., dose ranges to be deliv-
ered to the PTV and OARs are determined initially by the physician,
and dosimetry seeks to remain within these predeﬁned limits. IMRT
enables a tailored dose to be delivered within the volume to be
treated, several CTVs and thus several distinct PTVs being deﬁned.
Dose per PTV is determined according to risk of invasion (Fig. 3)
[12].
There are a number of IMRT techniques: SIB (Simultaneous
Integrated Boost), SMART (Simultaneous Modulated Accelerated
Radiation Therapy), or sequential (partially conformal 3D RT and
partially IMRT). In SIB the highest dose per fraction is delivered to
the highest-risk PTV, which usually includes the GTV, with lower
doses to medium or low-risk PTVs. High-risk PTV dose per fraction
is around 2 Gy/day. SMART combines integrated boost and accel-
erated radiation with a smaller number of fractions; high-risk PTV
dose per fraction is thus greater than 2.2 Gy/day, and often around
2.3 Gy/fraction [12].
Table 1 shows examples of dose levels and fractionation in
nasopharyngeal carcinoma IMRT [13–16].
4. Dose escalationtumoricidal dose of ≥ 70 Gy. Dose escalation has been described
in nasopharyngeal carcinoma, by brachytherapy or conformal or
stereotaxic radiation, but with increased late toxicity [17,18].
al GTV (red) and tumoral CTV (pink).
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Fig. 3. Example of dosimetry of a nasopharyngeal carcinoma (axial, sagittal and coronal slices). Red: high-risk PTV; dark blue: medium-risk PTV; turquoise: low-risk PTV.
Table 1
Examples of fractionation in IMRT.
Hong Kong [13,15] RTOG 0225 [14] MSKCC [16]
Technique SIB SIB SIB/2 plans SMART
High-risk PTV 70 Gy in 35 fractions of 2 Gy 70 Gy in 33 fractions of 2.12 Gy 70 Gy in 33 fractions of 2.12 Gy 70.2 Gy in 30 fractions of 2.34 Gy
Medium-risk PTV 63 Gy in 35 fractions of 1.8 Gy 60 Gy in 33 fractions of 1.82 Gy 59.4 Gy in 33 fractions of 1.8 Gy
of 1.64
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PLow-risk PTV 56 Gy in 35 fractions of 1.6 Gy 54 Gy in 33 fractions 
IB: simultaneous integrated boost; SMART: simultaneous modulated accelerated r
IMRT appears to be a promising means of increasing PTV doses
hile sparing OARs. Kwong et al., however, in a series of 50
atients with T3-T4 nasopharyngeal lesions treated by concomitant
hemotherapy and RT with IMRT up to 76 Gy by 2.17 Gy frac-
ions, reported 96% locoregional control at 25 months’ follow-up
ut increased late toxicity, with 4% of patients showing temporal
ecrosis and 4% severe epistaxis [19].
Late toxicities are mainly due to the increased dose per fraction.
pecial attention should therefore be paid to the risk of late OAR
oxicities in case of dose per fraction exceeding 2 Gy.
Thanks to the cellular hypoxia marker 18F-ﬂuoromisonidazole,
ET-CT may  in future improve the targeting of dose escalation.
his marker could indicate hypoxic and radioresistant tumor areas,
eﬁning an HTV (hypoxic tumor volume). A dosimetric study in 8
atients by Choi et al. reported a dose escalation in the HTV up to
8 Gy (by 2.6 Gy fractions) to be feasible in 75% of cases [20]. The
linical beneﬁt of this attitude remains to be proven.
. Beneﬁt of IMRT
.1. Local control
Dosimetric studies demonstrated beneﬁt for IMRT over con-
ormal RT in nasopharyngeal carcinoma, with improved dose
omogeneity and PTV coverage [21,22].
Peng et al. [23], in a prospective study, recently reported that
MRT provided signiﬁcantly better 5-year locoregional control than
able 2
ublications on IMRT in nasopharyngeal carcinoma.
Author Date Type of study Number of
patients
Stage
Lee [13] 2002 Retrospective 67 T1-4
Kwong [24] 2004 Retrospective 33 T1N0
Kam  [25] 2004 Retrospective 63 T1-4
Wolden [16] 2006 Retrospective 74 T1-4
Lin  [26] 2009 Retrospective 323 T2-4
Tham  [27] 2009 Retrospective 195 T1-4
Lee  [14] 2009 (RTOG) Prospective non-randomized 68 T1-4
Ng  [28] 2011 Retrospective 193 T1-4
Lai  [29] 2011 Retrospective 512 T1-4
Su  [30] 2012 Retrospective 198 T1-2
Wang  [31] 2013 Prospective non-randomized 300 T1-4 Gy 50.4 Gy (3D) 54 Gy in 30 fractions of 1.8 Gy
on therapy; 3D: 3D conformal radiation therapy.
2D RT (90% vs 85%, P = 0.04). However, no phase-III randomized
trials have as yet compared IMRT versus 3D conformal RT. Sev-
eral teams have published results, but retrospectively; the RTOG
0225 study is a non-randomized phase-II trial [13,14,16,24–31] (cf.
Table 2).
Even so, all series showed excellent control, exceeding 90%.
5.2. Protection of healthy organs
In nasopharyngeal carcinoma, radiation therapy may  induce
late complications due to partial irradiation of neighboring healthy
organs, also increased which concomitant chemotherapy: xerosto-
mia, dysphagia, dental problems, neurologic disorders (temporal
lobe necrosis, cranial nerve damage, impaired cognitive func-
tion, hearing loss), cervical ﬁbrosis, carotid stenosis, or endocrine
disorders due to involvement of the thyroid gland or hypothalamic-
pituitary axis.
Tuan et al. [32], in a large cohort of 796 patients treated by
exclusive 2D RT at 66–70 Gy, recently reported high rates of late
toxicities, with 73% of patients showing at least one complication
and, especially, a 46% rate of xerostomia (grade not speciﬁed).
Kam et al. [22] reported that IMRT signiﬁcantly reduced mean
and maximum OAR doses compared to 2D or 3D RT. Clinical ben-
eﬁt of such reduced OAR irradiation was reported by Peng et al.,
with signiﬁcantly fewer long-term side-effects (neurologic, sali-
vary, muscular and cutaneous toxicity) (P < 0.05), while Ma  et al.
 Median FU
(months)
Locoregional progression
free survival
Metastatic progression
free survival
N0-3 31 4 years: 98% 4 years: 66%
-1 24 3 years: 92% 3 years: 100%
N0-3 29 3 years: 98% 3 years: 79%
N0-3 35 3 years: 93% 3 years: 78%
N0-3 30 3 years: 98% 3 years: 90%
N0-3 36 3 years: 89% 3 years: 89%
N0-3 30 2 years: 91% 2 years: 85%
N0-3 30 2 years: 96% 2 years: 90%
N0-3 NR 5 years: 97% 5 years: 84%
N0-1 50 5 years: 98% 5 years: 98%
N0-3 47 4 years: 94% 4 years: 85%
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Table 3
Studies comparing late toxicity in nasopharyngeal cancer between IMRT and 3D or 2D RT.
Author (year) Study Number of
patients
TNM Salivary ﬂow (mL/min) EORCT QLQ H&N35 Xerostomia ≥ grade 2
Pow (2006) [34] IMRT versus 2D 51 T2N0-1 12 months
0.27 vs 0.05 (P < 0.001)
12 months (P < 0.001) NR
Kam  (2007) [35] IMRT versus 2D 60 T1-2N0-1 12 months
0.41 vs 0.20 (P < 0.001)
NR 1 year
39 vs 82% (P < 0.001)
Fang  (2008) [36] IMRT versus 3D 203 T1-4 N0-3 NR 12 months (P < 0.001) NR
Pow  (2011) [37] IMRT 57 T1-2N0-1 24 months
0.36
24 months (P < 0.001) NR
Peng  (2012) [23] IMRT versus 2D 616 T1-4 N0-3 NR NR > 6 months
N
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[R: not reported; EORTC QOL H&N 35: EORTC Quality of Life Scale.
eported improved quality of life at more than 2 years’ follow-up
23,33].
Three randomized studies compared IMRT versus 2D RT
23,34,35] and one prospective non-randomized study compared
MRT versus 3D RT [36]. On varying criteria (common toxicity crite-
ia, salivary ﬂow, quality of life), all four found signiﬁcantly lower
ates of xerostomia with IMRT (Table 3) [37].
In the future, OAR sparing may  be further enhanced by dynamic
rc therapy, enabling circular irradiation with continuous adapta-
ion of multileaf collimator positioning according to target and OAR
olumes. Initial dosimetric studies reported excellent conforma-
ion to target volumes, with improvement over conventional IMRT
nd reduced radiation time [38].
. Adaptive radiation therapy
In nasopharyngeal carcinoma, IMRT uses steep dose gradients
n dosimetric planning, especially for OARs such as the spinal cord
nd brainstem. This requires strict quality control before and during
herapy, notably including daily control of patient positioning.
Over 6–7 weeks’ treatment, anatomic changes may  neverthe-
ess appear, due to weight-loss, tumor response or salivary gland
ypotrophy, modifying the initially planned dosimetry with a risk
f increased OAR irradiation and poorer tumor volume cover.
Several authors have recommended a systematic second plan-
ing CT scan performed halfway through treatment, around the
5th fraction [39]. The clinical beneﬁt of this attitude remains to be
roven, and it cannot yet be recommended in routine practice [40].
. Conclusion
In recent years, IMRT has become the standard attitude in
asopharyngeal carcinoma. It optimizes target volume cover and
llows signiﬁcantly less irradiation of healthy organs than conven-
ional 2D or 3D RT. This leads to a lower rate of late toxicities,
otably xerostomia. Beneﬁt with respect to 3D RT in terms of
ocoregional control and survival, however, has yet to be demon-
trated in randomized trials, although all data published to date
eported excellent rates of local control: > 90% at 3 years.
Improved locoregional control and survival in nasopharyn-
eal carcinoma may  be achieved by dose escalation targeted
y metabolic imaging (18-ﬂuoromisonidazole (F-MISO) PET), or
ssociated targeted therapies (bevacizumab, cetuximab) to avoid
etastatic failure.
Late toxicity may  be also reduced by arc therapy, enhancing OAR
paring.isclosure of interest
F. Huguet: Merck, Roche.
[30 vs 69% (P < 0.001)
S. Haberer-Guillerm and E. Touboul declare that they have no
conﬂicts of interest concerning this article.
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